| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:SPA70;SPA70,Inhibitor,cancer,hPXR,SPA 70,inhibit,pregnane X receptor,SPA-70
CAS:931314-31-7
Purity:98.34% Package:1 mg;10 mg;100 mg;200 mg;25 mg;5 mg;50 mg
|
| Company Name: |
Nantong QuanYi Biotechnology Co., Ltd
|
| Tel: |
0513-66337626 18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:Specific PXR antagonist 70
CAS:931314-31-7
Purity:98%+ HPLC Package:10mg，100mg，500mg，1g，2g，5g，10g，more
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:Specific PXR antagonist 70；
CAS:931314-31-7
Purity:98.34% Package:详见官网
|
|
| | 4-(4-tert-butylbenzenesulfonyl)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole Basic information |
| Product Name: | 4-(4-tert-butylbenzenesulfonyl)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole | | Synonyms: | 4-(4-tert-butylbenzenesulfonyl)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole;SPA70,Inhibitor,cancer,hPXR,SPA 70,inhibit,pregnane X receptor,SPA-70;1H-1,2,3-Triazole, 1-(2,5-dimethoxyphenyl)-4-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-5-methyl-;SPA70-LC-1|SpecificPXRantagonist70;Specific PXR antagonist 70 | | CAS: | 931314-31-7 | | MF: | C21H25N3O4S | | MW: | 415.51 | | EINECS: | | | Product Categories: | | | Mol File: | 931314-31-7.mol |  |
| | 4-(4-tert-butylbenzenesulfonyl)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole Chemical Properties |
| Boiling point | 612.6±65.0 °C(Predicted) | | density | 1.22±0.1 g/cm3(Predicted) | | solubility | Chloroform: 10 mg/ml | | form | A solid | | pka | -7.17±0.70(Predicted) | | color | Off-white to pink |
| | 4-(4-tert-butylbenzenesulfonyl)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole Usage And Synthesis |
| Biological Activity | SPA70 is a pregnane X receptor (PXR) antagonist (IC50 = 0.51 μM).1 It is selective for PXR over 10 additional nuclear receptors at concentrations greater than 5 μM, as well as over a panel of 384 kinases at 10 μM. SPA70 (0.1-10 μM) inhibits PXR activation induced by rifampicin in HEK293 cells expressing the human receptor. It also inhibits rifampicin-induced activity of the PXR target cytochrome P450 (CYP) isoform 3A4 (CYP3A4) in primary human hepatocytes. SPA70 (200 mg/kg) inhibits PXR agonist-induced CYP3A4-mediated metabolism of midazolam and paclitaxel in human PXR transgenic (hPXR-tg) mice. | | References | 1.Lin, W., Wang, Y.-M., Chai, S.C., et al.SPA70 is a potent antagonist of human pregnane X receptorNat. Commun.8(1)741(2017) |
| | 4-(4-tert-butylbenzenesulfonyl)-1-(2,5-dimethoxyphenyl)-5-methyl-1H-1,2,3-triazole Preparation Products And Raw materials |
|